Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis
Aim Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients. Method Consecutive patients were enrolled between Ma...
Saved in:
Published in | International journal of rheumatic diseases Vol. 24; no. 6; pp. 781 - 788 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.06.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim
Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients.
Method
Consecutive patients were enrolled between May 2016 and December 2017. Serum was collected within 72 hours of commencing corticosteroids and at 6 months. It was analyzed for levels of intra‐cellular adhesion molecule 1, vascular endothelial growth factor (VEGF), pentraxin 3, von Willebrand factor and procalcitonin (5‐plex R&D Systems multiplex assay) and interleukin (IL)6, IL12 and interferon‐γ (high‐sensitivity 3‐plex ProcartaPlex multiplex assay). A GCA specific positron emission tomography / computed tomography (PET/CT) scan was performed at enrolment with uptake in each vascular territory graded and summed to derive a total vascular score (TVS).
Results
For the 63 patients enrolled, 12 (19%) had a final diagnosis of biopsy‐positive GCA and a further 9 had a clinical diagnosis of biopsy‐negative GCA. None of the 8 biomarkers was significantly higher in GCA patients compared with those with alternative diagnoses, or demonstrated a positive correlation with the PET/CT TVS. This was in contrast to the C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR) which were higher in the biopsy‐positive GCA cohort (P < .04) and showed weak positive correlations with the TVS (correlation coefficient 0.34, P < .01). Procalcitonin did not distinguish between GCA and infection. Concentrations of CRP, ESR, VEGF and pentraxin 3 decreased between diagnosis and 6 months in GCA patients.
Conclusion
This study did not identify new serological biomarkers to assist in diagnosing or assessing the vasculitis burden in GCA. |
---|---|
AbstractList | Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients.
Consecutive patients were enrolled between May 2016 and December 2017. Serum was collected within 72 hours of commencing corticosteroids and at 6 months. It was analyzed for levels of intra-cellular adhesion molecule 1, vascular endothelial growth factor (VEGF), pentraxin 3, von Willebrand factor and procalcitonin (5-plex R&D Systems multiplex assay) and interleukin (IL)6, IL12 and interferon-γ (high-sensitivity 3-plex ProcartaPlex multiplex assay). A GCA specific positron emission tomography / computed tomography (PET/CT) scan was performed at enrolment with uptake in each vascular territory graded and summed to derive a total vascular score (TVS).
For the 63 patients enrolled, 12 (19%) had a final diagnosis of biopsy-positive GCA and a further 9 had a clinical diagnosis of biopsy-negative GCA. None of the 8 biomarkers was significantly higher in GCA patients compared with those with alternative diagnoses, or demonstrated a positive correlation with the PET/CT TVS. This was in contrast to the C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) which were higher in the biopsy-positive GCA cohort (P < .04) and showed weak positive correlations with the TVS (correlation coefficient 0.34, P < .01). Procalcitonin did not distinguish between GCA and infection. Concentrations of CRP, ESR, VEGF and pentraxin 3 decreased between diagnosis and 6 months in GCA patients.
This study did not identify new serological biomarkers to assist in diagnosing or assessing the vasculitis burden in GCA. Aim Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients. Method Consecutive patients were enrolled between May 2016 and December 2017. Serum was collected within 72 hours of commencing corticosteroids and at 6 months. It was analyzed for levels of intra‐cellular adhesion molecule 1, vascular endothelial growth factor (VEGF), pentraxin 3, von Willebrand factor and procalcitonin (5‐plex R&D Systems multiplex assay) and interleukin (IL)6, IL12 and interferon‐γ (high‐sensitivity 3‐plex ProcartaPlex multiplex assay). A GCA specific positron emission tomography / computed tomography (PET/CT) scan was performed at enrolment with uptake in each vascular territory graded and summed to derive a total vascular score (TVS). Results For the 63 patients enrolled, 12 (19%) had a final diagnosis of biopsy‐positive GCA and a further 9 had a clinical diagnosis of biopsy‐negative GCA. None of the 8 biomarkers was significantly higher in GCA patients compared with those with alternative diagnoses, or demonstrated a positive correlation with the PET/CT TVS. This was in contrast to the C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR) which were higher in the biopsy‐positive GCA cohort (P < .04) and showed weak positive correlations with the TVS (correlation coefficient 0.34, P < .01). Procalcitonin did not distinguish between GCA and infection. Concentrations of CRP, ESR, VEGF and pentraxin 3 decreased between diagnosis and 6 months in GCA patients. Conclusion This study did not identify new serological biomarkers to assist in diagnosing or assessing the vasculitis burden in GCA. AIMDiagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients. METHODConsecutive patients were enrolled between May 2016 and December 2017. Serum was collected within 72 hours of commencing corticosteroids and at 6 months. It was analyzed for levels of intra-cellular adhesion molecule 1, vascular endothelial growth factor (VEGF), pentraxin 3, von Willebrand factor and procalcitonin (5-plex R&D Systems multiplex assay) and interleukin (IL)6, IL12 and interferon-γ (high-sensitivity 3-plex ProcartaPlex multiplex assay). A GCA specific positron emission tomography / computed tomography (PET/CT) scan was performed at enrolment with uptake in each vascular territory graded and summed to derive a total vascular score (TVS). RESULTSFor the 63 patients enrolled, 12 (19%) had a final diagnosis of biopsy-positive GCA and a further 9 had a clinical diagnosis of biopsy-negative GCA. None of the 8 biomarkers was significantly higher in GCA patients compared with those with alternative diagnoses, or demonstrated a positive correlation with the PET/CT TVS. This was in contrast to the C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) which were higher in the biopsy-positive GCA cohort (P < .04) and showed weak positive correlations with the TVS (correlation coefficient 0.34, P < .01). Procalcitonin did not distinguish between GCA and infection. Concentrations of CRP, ESR, VEGF and pentraxin 3 decreased between diagnosis and 6 months in GCA patients. CONCLUSIONThis study did not identify new serological biomarkers to assist in diagnosing or assessing the vasculitis burden in GCA. |
Author | Nguyen, Katherine Laurent, Rodger Sammel, Anthony M. Karsten, Elisabeth Smith, Susan Xue, Meilang Little, Christopher B. |
Author_xml | – sequence: 1 givenname: Anthony M. orcidid: 0000-0003-3641-796X surname: Sammel fullname: Sammel, Anthony M. email: anthony.sammel@health.nsw.gov.au organization: University of New South Wales – sequence: 2 givenname: Meilang surname: Xue fullname: Xue, Meilang organization: Kolling Institute, Faculty of Medicine and Health, The University of Sydney – sequence: 3 givenname: Elisabeth surname: Karsten fullname: Karsten, Elisabeth organization: Sangui Bio Pty Ltd. Kolling Institute – sequence: 4 givenname: Christopher B. surname: Little fullname: Little, Christopher B. organization: Kolling Institute, Faculty of Medicine and Health, University of Sydney – sequence: 5 givenname: Susan surname: Smith fullname: Smith, Susan organization: Kolling Institute, Faculty of Medicine and Health, University of Sydney – sequence: 6 givenname: Katherine surname: Nguyen fullname: Nguyen, Katherine organization: Royal North Shore Hospital – sequence: 7 givenname: Rodger surname: Laurent fullname: Laurent, Rodger organization: University of Sydney |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33847438$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUtrGzEURkVIyHvdXRF0042T0eg1XpqQNgVDskggO6HR3HHkypIraWz876uJUy-6ibTQg3MPl-9eoGMfPCD0hVQ3pKxbIrmYkIa_3hBW3kfo_PBzfLgzcoYuUlpWlSBUyFN0RmnDJKPNOVrO7cpm6PCQrbN5h0OPfdiAwwlicGFhjXa4tWGl42-ICVuP1zpb8DlhD1u3w2lIazCjo9S-6Y31C7yw2mdswDmsY4Zos01X6KTXLsH1x3mJXn7cP989TOaPP3_dzeYTw6gkEyFl1TZGl801qzpeM8ME7UTXGkl0T9mUNNowrmtOpdS1YD20wOu2Mz3rKL1E3_fedQx_BkhZrWwaW9EewpBUzUlNGZ2SEf32H7oMQ_SlOzXKhWAlsELd7ikTQ0oRerWOtuSxU6RS4xjUGLQaQ1fvYygVXz-8Q7uC7sD_y70AfA9srYPdZz41e5rvxX8BtpKVLA |
CitedBy_id | crossref_primary_10_1016_j_cca_2023_117592 crossref_primary_10_1080_03009742_2022_2047311 crossref_primary_10_3389_fimmu_2022_1066916 crossref_primary_10_1055_a_1942_6311 |
Cites_doi | 10.1002/art.1780330810 10.1136/annrheumdis-2019-215697 10.1136/annrheumdis-2013-204572 10.1093/rheumatology/ker163 10.1007/s40674-016-0043-x 10.1097/ICU.0000000000000528 10.1136/rmdopen-2016-000353 10.1080/08916930903002495 10.1016/S1473-3099(17)30592-3 10.1002/art.1780360913 10.1186/1471-2172-10-52 10.1002/art.22368 10.1038/nrrheum.2013.161 10.1136/ard.53.8.521 10.1002/art.1780270912 10.1002/art.40864 10.1056/NEJMoa1613849 10.1097/01.md.0000180043.19285.54 10.1136/ard.55.12.927 10.1136/ard.50.5.316 10.1161/CIRCULATIONAHA.109.872903 10.1038/nrneph.2017.51 10.1136/annrheumdis-2018-214704 10.1016/j.autrev.2017.05.014 10.1136/ard.58.3.189 10.1097/01.md.0000180042.42156.d1 10.1136/annrheumdis-2019-215672 10.1016/j.semarthrit.2011.10.005 10.1002/art.33411 10.1186/s13075-016-1184-x 10.1093/rheumatology/keu526 10.1111/1756-185X.13702 10.1002/acr.20043 10.1001/jama.287.1.92 10.1093/rheumatology/keq039a 10.1186/s12916-017-0795-7 |
ContentType | Journal Article |
Copyright | 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. International Journal of Rheumatic Diseases © 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd |
Copyright_xml | – notice: 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. – notice: International Journal of Rheumatic Diseases © 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd |
DBID | NPM AAYXX CITATION 7QP 7T5 H94 7X8 |
DOI | 10.1111/1756-185X.14111 |
DatabaseName | PubMed CrossRef Calcium & Calcified Tissue Abstracts Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef AIDS and Cancer Research Abstracts Calcium & Calcified Tissue Abstracts Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-185X |
EndPage | 788 |
ExternalDocumentID | 10_1111_1756_185X_14111 33847438 APL14111 |
Genre | article Journal Article |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 29J 31~ 33P 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA HF~ HGLYW HVGLF HZI HZ~ IX1 K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 ~IA ~WT NPM AAMNL AAYXX ACRPL ACYXJ CITATION 7QP 7T5 H94 7X8 |
ID | FETCH-LOGICAL-c4371-6770b8cacac5a40d524c463d6dbc71af34918ac45a25377a264febe52bdcf4d33 |
IEDL.DBID | DR2 |
ISSN | 1756-1841 |
IngestDate | Wed Dec 04 06:47:03 EST 2024 Tue Nov 19 05:20:58 EST 2024 Fri Dec 06 04:26:55 EST 2024 Sat Sep 28 08:23:29 EDT 2024 Sat Aug 24 01:03:44 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | giant cell arteritis vasculitis interleukin-6 enzyme-linked immunosorbent assay immunoassay |
Language | English |
License | 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4371-6770b8cacac5a40d524c463d6dbc71af34918ac45a25377a264febe52bdcf4d33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-3641-796X |
PMID | 33847438 |
PQID | 2537664136 |
PQPubID | 1086355 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_2512343913 proquest_journals_2537664136 crossref_primary_10_1111_1756_185X_14111 pubmed_primary_33847438 wiley_primary_10_1111_1756_185X_14111_APL14111 |
PublicationCentury | 2000 |
PublicationDate | June 2021 |
PublicationDateYYYYMMDD | 2021-06-01 |
PublicationDate_xml | – month: 06 year: 2021 text: June 2021 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Richmond |
PublicationTitle | International journal of rheumatic diseases |
PublicationTitleAlternate | Int J Rheum Dis |
PublicationYear | 2021 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2018; 29 2019; 71 1990; 33 2017; 3 2009; 42 1984; 27 2019; 78 1991; 50 2015; 54 2005; 84 2010; 121 2020; 79 2016; 18 2017; 377 2007; 56 2010; 62 2013; 9 1996; 55 1993; 36 2018; 18 2010; 49 2016; 2 2009; 10 2017; 15 2019; 22 2017; 16 2002; 287 2017; 13 2011; 50 2008; 28 1999; 58 2008; 26 2014; 73 2012; 64 2012; 41 1994; 53 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 e_1_2_6_37_1 Maruotti N (e_1_2_6_9_1) 2008; 26 e_1_2_6_21_1 e_1_2_6_20_1 Remahl AI (e_1_2_6_22_1) 2008; 28 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_29_1 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 |
References_xml | – volume: 55 start-page: 927 issue: 12 year: 1996 end-page: 930 article-title: Von Willebrand factor in the outcome of temporal arteritis publication-title: Ann Rheum Dis – volume: 62 start-page: 835 issue: 6 year: 2010 end-page: 841 article-title: Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin‐6) in the long‐term followup of patients with giant cell arteritis publication-title: Arthritis Care Res – volume: 27 start-page: 1046 issue: 9 year: 1984 end-page: 1049 article-title: Elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment in giant cell arteritis publication-title: Arthritis Rheum – volume: 29 start-page: 520 issue: 6 year: 2018 end-page: 527 article-title: Update on giant cell arteritis publication-title: Curr Opin Ophthalmol – volume: 58 start-page: 189 issue: 3 year: 1999 end-page: 192 article-title: Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule‐1 (sICAM‐1) concentrations and disease activity publication-title: Ann Rheum Dis – volume: 26 start-page: 476 issue: 3 year: 2008 end-page: 483 article-title: Angiogenesis in vasculitides publication-title: Clin Exp Rheumatol – volume: 121 start-page: 906 issue: 7 year: 2010 end-page: 915 article-title: Th17 and Th1 T‐cell responses in giant cell arteritis publication-title: Circulation – volume: 15 start-page: 15 issue: 1 year: 2017 article-title: Procalcitonin‐guided diagnosis and antibiotic stewardship revisited publication-title: BMC Med – volume: 36 start-page: 1286 issue: 9 year: 1993 end-page: 1294 article-title: Correlation of interleukin‐6 production and disease activity in polymyalgia rheumatica and giant cell arteritis publication-title: Arthritis Rheum – volume: 49 start-page: 1594 issue: 8 year: 2010 end-page: 1597 article-title: BSR and BHPR guidelines for the management of giant cell arteritis publication-title: Rheumatology (Oxford) – volume: 78 start-page: 1012 issue: 7 year: 2019 end-page: 1014 article-title: Serial IL‐6 measurements in patients with tocilizumab‐treated large‐vessel vasculitis detect infections and may predict early relapses publication-title: Ann Rheum Dis – volume: 53 start-page: 521 issue: 8 year: 1994 end-page: 524 article-title: Circadian rhythm of serum interleukin‐6 in rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 84 start-page: 269 issue: 5 year: 2005 end-page: 276 article-title: Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients publication-title: Medicine – volume: 10 start-page: 52 year: 2009 article-title: Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays publication-title: BMC Immunol – volume: 18 start-page: 95 issue: 1 year: 2018 end-page: 107 article-title: Effect of procalcitonin‐guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta‐analysis publication-title: Lancet Infect Dis – volume: 41 start-page: 866 issue: 6 year: 2012 end-page: 871 article-title: Utility of erythrocyte sedimentation rate and C‐reactive protein for the diagnosis of giant cell arteritis publication-title: Semin Arthritis Rheum – volume: 50 start-page: 316 issue: 5 year: 1991 end-page: 320 article-title: von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis publication-title: Ann Rheum Dis – volume: 79 start-page: 19 issue: 1 year: 2020 end-page: 30 article-title: 2018 Update of the EULAR recommendations for the management of large vessel vasculitis publication-title: Ann Rheum Dis – volume: 84 start-page: 277 issue: 5 year: 2005 end-page: 290 article-title: Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients publication-title: Medicine – volume: 33 start-page: 1122 issue: 8 year: 1990 end-page: 1128 article-title: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis publication-title: Arthritis Rheum – volume: 13 start-page: 368 issue: 6 year: 2017 end-page: 380 article-title: The immunology of atherosclerosis publication-title: Nat Rev Nephrol – volume: 2 start-page: 126 issue: 2 year: 2016 end-page: 137 article-title: Giant cell arteritis: from pathogenesis to therapeutic management publication-title: Curr Treat Options Rheumatol – volume: 18 start-page: 283 issue: 1 year: 2016 article-title: Vascular endothelial growth factor levels and rheumatic diseases of the elderly publication-title: Arthritis Res Ther – volume: 64 start-page: 854 issue: 3 year: 2012 end-page: 865 article-title: Selective up‐regulation of the soluble pattern‐recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia publication-title: Arthritis Rheum – volume: 28 start-page: 157 issue: 2 year: 2008 end-page: 163 article-title: Comparison of soluble ICAM‐1, VCAM‐1 and E‐selectin levels in patients with episodic cluster headache and giant cell arteritis publication-title: Cephalalgia – volume: 54 start-page: 1397 issue: 8 year: 2015 end-page: 1402 article-title: Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica publication-title: Rheumatology (Oxford) – volume: 56 start-page: 399 issue: 2 year: 2007 end-page: 408 article-title: Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management publication-title: Arthritis Rheum – volume: 16 start-page: 833 issue: 8 year: 2017 end-page: 844 article-title: Recent advances in our understanding of giant cell arteritis pathogenesis publication-title: Autoimmun Rev – volume: 3 issue: 1 year: 2017 article-title: Is vascular endothelial growth factor a useful biomarker in giant cell arteritis? publication-title: RMD open – volume: 287 start-page: 92 issue: 1 year: 2002 end-page: 101 article-title: Does this patient have temporal arteritis? publication-title: JAMA – volume: 50 start-page: 2061 issue: 11 year: 2011 end-page: 2070 article-title: Tissue and serum markers of inflammation during the follow‐up of patients with giant‐cell arteritis–a prospective longitudinal study publication-title: Rheumatology (Oxford) – volume: 22 start-page: 1900 issue: 10 year: 2019 end-page: 1904 article-title: Circulating interleukin‐6 as a biomarker in a randomized controlled trial of modified‐release prednisone vs immediate‐release prednisolone, in newly diagnosed patients with giant cell arteritis publication-title: Int J Rheum Dis – volume: 79 start-page: e102 issue: 8 year: 2020 article-title: Analysis of IL‐6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone publication-title: Ann Rheum Dis – volume: 71 start-page: 1319 issue: 8 year: 2019 end-page: 1328 article-title: Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double‐blind, cross‐sectional study publication-title: Arthritis Rheum – volume: 42 start-page: 596 issue: 7 year: 2009 end-page: 604 article-title: Vascular damage in giant cell arteritis publication-title: Autoimmunity – volume: 73 start-page: 1388 issue: 7 year: 2014 end-page: 1392 article-title: Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy‐proven giant cell arteritis: a prospective, case‐control study publication-title: Ann Rheum Dis – volume: 9 start-page: 731 issue: 12 year: 2013 end-page: 740 article-title: Immune mechanisms in medium and large‐vessel vasculitis publication-title: Nat Rev Rheumatol – volume: 377 start-page: 317 issue: 4 year: 2017 end-page: 328 article-title: Trial of tocilizumab in giant‐cell arteritis publication-title: N Engl J Med – ident: e_1_2_6_19_1 doi: 10.1002/art.1780330810 – ident: e_1_2_6_34_1 doi: 10.1136/annrheumdis-2019-215697 – ident: e_1_2_6_29_1 doi: 10.1136/annrheumdis-2013-204572 – ident: e_1_2_6_14_1 doi: 10.1093/rheumatology/ker163 – ident: e_1_2_6_6_1 doi: 10.1007/s40674-016-0043-x – ident: e_1_2_6_8_1 doi: 10.1097/ICU.0000000000000528 – ident: e_1_2_6_10_1 doi: 10.1136/rmdopen-2016-000353 – ident: e_1_2_6_27_1 doi: 10.1080/08916930903002495 – ident: e_1_2_6_36_1 doi: 10.1016/S1473-3099(17)30592-3 – ident: e_1_2_6_32_1 doi: 10.1002/art.1780360913 – ident: e_1_2_6_37_1 doi: 10.1186/1471-2172-10-52 – volume: 28 start-page: 157 issue: 2 year: 2008 ident: e_1_2_6_22_1 article-title: Comparison of soluble ICAM‐1, VCAM‐1 and E‐selectin levels in patients with episodic cluster headache and giant cell arteritis publication-title: Cephalalgia contributor: fullname: Remahl AI – ident: e_1_2_6_38_1 doi: 10.1002/art.22368 – ident: e_1_2_6_7_1 doi: 10.1038/nrrheum.2013.161 – ident: e_1_2_6_39_1 doi: 10.1136/ard.53.8.521 – ident: e_1_2_6_13_1 doi: 10.1002/art.1780270912 – ident: e_1_2_6_18_1 doi: 10.1002/art.40864 – ident: e_1_2_6_28_1 doi: 10.1056/NEJMoa1613849 – ident: e_1_2_6_5_1 doi: 10.1097/01.md.0000180043.19285.54 – ident: e_1_2_6_11_1 doi: 10.1136/ard.55.12.927 – ident: e_1_2_6_12_1 doi: 10.1136/ard.50.5.316 – ident: e_1_2_6_24_1 doi: 10.1161/CIRCULATIONAHA.109.872903 – volume: 26 start-page: 476 issue: 3 year: 2008 ident: e_1_2_6_9_1 article-title: Angiogenesis in vasculitides publication-title: Clin Exp Rheumatol contributor: fullname: Maruotti N – ident: e_1_2_6_25_1 doi: 10.1038/nrneph.2017.51 – ident: e_1_2_6_33_1 doi: 10.1136/annrheumdis-2018-214704 – ident: e_1_2_6_17_1 doi: 10.1016/j.autrev.2017.05.014 – ident: e_1_2_6_23_1 doi: 10.1136/ard.58.3.189 – ident: e_1_2_6_3_1 doi: 10.1097/01.md.0000180042.42156.d1 – ident: e_1_2_6_21_1 doi: 10.1136/annrheumdis-2019-215672 – ident: e_1_2_6_4_1 doi: 10.1016/j.semarthrit.2011.10.005 – ident: e_1_2_6_15_1 doi: 10.1002/art.33411 – ident: e_1_2_6_26_1 doi: 10.1186/s13075-016-1184-x – ident: e_1_2_6_30_1 doi: 10.1093/rheumatology/keu526 – ident: e_1_2_6_16_1 doi: 10.1111/1756-185X.13702 – ident: e_1_2_6_31_1 doi: 10.1002/acr.20043 – ident: e_1_2_6_2_1 doi: 10.1001/jama.287.1.92 – ident: e_1_2_6_20_1 doi: 10.1093/rheumatology/keq039a – ident: e_1_2_6_35_1 doi: 10.1186/s12916-017-0795-7 |
SSID | ssj0061367 |
Score | 2.2910128 |
Snippet | Aim
Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed... Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the... AimDiagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed... AIMDiagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 781 |
SubjectTerms | Arteritis Biomarkers Biopsy Computed tomography Corticosteroids Diagnosis enzyme‐linked immunosorbent assay Erythrocyte sedimentation rate giant cell arteritis immunoassay Interferon Interleukin 1 Interleukin 12 interleukin‐6 Pentraxins Positron emission tomography Procalcitonin Serology Vascular endothelial growth factor Vasculitis Von Willebrand factor |
Title | Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1756-185X.14111 https://www.ncbi.nlm.nih.gov/pubmed/33847438 https://www.proquest.com/docview/2537664136 https://search.proquest.com/docview/2512343913 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8UwEB7Eg3hxX-pGBA9eKk2TJu1RXBBREVHwVpK0FRf6xL4n6K93Jm0fLgcR6SXQpM0yk_mSzHwB2OFcOadEFFqlZShVlIZpmqFeFTyu0iypYr-VfX6hTm7k6W3SexNSLEzLDzHecCPN8PM1KbixzSclR7unQrQ2t6js3Ef3cqHJqe_wakwgpYiQzIdE-rySd-Q-5MvzrfxXu_QDbH7Frt74HM-C7avd-pw87o2Gds-9f2N0_Fe75mCmg6Zsv5WleZgo6wWYOu8O3xfhoQuGYiirBN7ZoGL14LV8YijG_RzKKJ6fXH5eGnZfs462tWGI3p_eWDPykZ34DSxL_AD1HbtDAR0yOkBg3r-USJaW4Ob46PrgJOyuagidFJqHSuvIps7gkxgZFUksnVSCbqtymptKyIynxsnExInQ2iAMq1B8ktgWrpKFEMswWQ_qchWYtBYnPhNlIq0k4hVLt4NEujCyitHOZgHs9gOVP7eMHHm_kqG-y6nvct93AWz0A5l3qtnkVAGl0HarALbHr1GpqKGmLgcjyoMGnWKSRQArrQCM_4VreomwKw2gHcbfKpHvX575xNpfC6zDdEweNH7PZwMmhy-jchMh0NBueSn_ABUH-bA |
link.rule.ids | 314,780,784,1375,27924,27925,46294,46718 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8QwEB5EQX3xPuoZwQdfKk2Tpu2jeLDqrogo7FtJ03bxoCvurqC_3pm0XTweRKQvhSZpjpnMl2TmC8A-58oYJTw3VaF0pfIiN4pi1KuM-0UUB4Vvt7I7V6p1Jy-6QfdTLEzFDzHecCPNsPM1KThtSH_ScjR8ykVz00Vt5xTeO4VKz8mt6-RmTCGliJLMBkXaxJLX9D7kzfOtgK-W6Qfc_Iperfk5mwfTVLzyOnk8HA3TQ_P-jdPxfy1bgLkanbKjSpwWYSIvl2C6U5-_L8NDHQ_FUFwJv7N-wcr-a_7EUJKbaZRRSD95_bwM2H3JaubWAUMA__TGBiMb3IllYF6iCCh7rIcyOmR0hsCsiynxLK3A3dnp7XHLrW9rcI0UIXdVGHppZDQ-gZZeFvjSSCXowioTcl0IGfNIGxloPxBhqBGJFShBgZ9mppCZEKswWfbLfB2YTFOc-7QXi6iQCFlSuiDECzMtCx9NbezAQTNSyXNFypE0ixnqu4T6LrF958BWM5JJrZ2DhCqgFJpv5cDe-DPqFTVUl3l_RGnQplNYsnBgrZKA8b9wWS8ReUUOVOP4WyWSo-u2fdn4a4ZdmGnddtpJ-_zqchNmfXKosVtAWzA5fBnl24iIhumOFfkPzvP90Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8UwEB5EQby4L3WN4MFLpW3StD2K-nBHRMFbSdLm4UKf-N4T9Nc7k7YPl4OI9FJokmaZyXxJZr4A7IShNEbywNcyEb6QQeqnaYZ6VYSRTbPYRm4r--JSHt-K07u49SakWJiaH2K04Uaa4eZrUvDnwn5ScrR70kdrc4fKHlJ074SQUUb0-YfXIwYpSYxkLibSJRZhw-5DzjzfCvhqmH6gza_g1Vmfzgzott6108nj3nCg98z7N0rHfzVsFqYbbMr2a2Gag7GymofJi-b0fQEemmgohsJK6J31LKt6r-UTQzluJ1FGAf3k8_PSZ_cVa3hb-wzh-9Mb6w9daCeWgXmJIKDqsi5K6IDRCQJzDqbEsrQIt52jm4Njv7mrwTeCJ6EvkyTQqVH4xEoERRwJIySn66pMEirLRRamyohYRTFPEoU4zKL8xJEujBUF50swXvWqcgWY0BpnPhVkPLUCAYum60GCpFDCRmhoMw9224HKn2tKjrxdylDf5dR3ues7D9bbgcwb3eznVAEp0XhLD7ZHn1GrqKGqKntDSoMWnYKSuQfLtQCM_oWLeoG4K_WgHsbfKpHvX527l9W_ZtiCyavDTn5-cnm2BlMRedO4_Z91GB-8DMsNhEMDvekE_gPMNvyA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Limited+utility+of+novel+serological+biomarkers+in+patients+newly+suspected+of+having+giant+cell+arteritis&rft.jtitle=International+journal+of+rheumatic+diseases&rft.au=Sammel%2C+Anthony+M.&rft.au=Xue%2C+Meilang&rft.au=Karsten%2C+Elisabeth&rft.au=Little%2C+Christopher+B.&rft.date=2021-06-01&rft.issn=1756-1841&rft.eissn=1756-185X&rft.volume=24&rft.issue=6&rft.spage=781&rft.epage=788&rft_id=info:doi/10.1111%2F1756-185X.14111&rft.externalDBID=10.1111%252F1756-185X.14111&rft.externalDocID=APL14111 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-1841&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-1841&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-1841&client=summon |